{"name":"Phathom Pharmaceuticals","slug":"phathom","ticker":"PHAT","exchange":"NASDAQ","domain":"phathompharma.com","description":"Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","hq":"Florham Park, NJ","founded":0,"employees":"371","ceo":"Terrie Curran","sector":"Gastroenterology","stockPrice":11.92,"stockChange":0.37,"stockChangePercent":3.2,"marketCap":"$939M","metrics":{"revenue":175110000,"revenueGrowth":94.1,"grossMargin":87.1,"rdSpend":32780000,"netIncome":-221247000,"cash":129972000,"dividendYield":0,"peRatio":7.7,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Vonoprazan patent cliff ($1.2B at risk)","drug":"Vonoprazan","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Vonoprazan ODT-1 or ODT-2 without Water","genericName":"Vonoprazan ODT-1 or ODT-2 without Water","slug":"vonoprazan-odt-1-or-odt-2-without-water","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Vonoprazan ODT-1 or ODT-2 without Water","genericName":"Vonoprazan ODT-1 or ODT-2 without Water","slug":"vonoprazan-odt-1-or-odt-2-without-water","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-27","type":"regulatory","headline":"Phathom Pharmaceuticals Announces FDA Approval of Vonoprazan for Treatment of Gastroesophageal Reflux Disease (GERD)","summary":"Phathom Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved vonoprazan for the treatment of GERD in adults.","drugName":"Vonoprazan","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results","summary":"Phathom Pharmaceuticals reported its financial results for the third quarter of 2022, with a net loss of $34.3 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-01","type":"deal","headline":"Phathom Pharmaceuticals Announces Collaboration with Takeda Pharmaceutical Company Limited","summary":"Phathom Pharmaceuticals announced a collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize vonoprazan in Japan.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-27","type":"earnings","source":"simplywall.st","summary":"Phathom Pharmaceuticals (PHAT) Losses Narrow To US$0.29 EPS And Test Bullish Profitability Narrative - simplywall.st","headline":"Phathom Pharmaceuticals (PHAT) Losses Narrow To US$0.29 EPS And Test Bullish Profitability Narrative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPQ2xXb1YyeWNrVzVsT1BtemxnQmRRMWxZLW1tSHBLTEQtU0FJTUhROGtNUF9XN2pRMHQ3S05tXzZETi1mUENKVWRCZExLZEpxbHhON2phUkVla2Z0VG9zZjBKVm43bU5NNVd4ZVJVZm9oSks0NmlJTFE2LWExa2d5SkNkRnJ5X2sxMkRpbXB2X1gwaUxkdEpiLS0wTnRFRUFycnhwU1I5a3R0aG9sSzBoemc0SThuSVR6dFBfRA?oc=5","date":"2026-02-26","type":"earnings","source":"Stock Titan","summary":"Heartburn drug VOQUEZNA tops 1.1M prescriptions as Phathom targets 2026 profit - Stock Titan","headline":"Heartburn drug VOQUEZNA tops 1.1M prescriptions as Phathom targets 2026 profit","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNUWQwekN6T0g3S2E0UjZacXg2YmZNNmNicThTSnpvR1BQU3NEZGJJS2VWdFNvVlZQZ0tXT2tlSDgyNU9xbGU4WXdjdXF2UVFUY3h3TERKekwyYmFwc0FvVGpjVlNUWXhYeDgyektBSzdnaEpNRnN1ci1FeExCcllSN3VhRlRKemRQbG90RHhtTkUwM1JadGh5Mk9pS2lWT0UtNkVIRUV0YTN3RE1PcnBSWXZlREZNMkJQSjE3MkVxSjFXdw?oc=5","date":"2026-02-19","type":"regulatory","source":"AD HOC NEWS","summary":"Phathom Pharma’s FDA Win: Why This Beaten-Down Biotech Suddenly Matters - AD HOC NEWS","headline":"Phathom Pharma’s FDA Win: Why This Beaten-Down Biotech Suddenly Matters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOcjNPZ3V5S2UzRFl2OWxwQkhQX0RtSFhTcGVaUVBVNkJDNklTczBZVjNPTWxBWnpQSlA4SGpsNUtDVXA5Q1BmTHhucmVMUGdPNjZTYnFfRXFLVmlrTjF2V21rTUpMY3liRktFbnJnMkhqNDBObUNiVUhYWHFGSldsUDctUmRMdGZmVW1GUWIxNVBzNTV6MUczdXVlbmhrTWNsUkZfQWc0ZTNFQ3BmSVJWcGxWUU5CRFc1UFozd0Zwbw?oc=5","date":"2026-02-17","type":"pipeline","source":"Stock Titan","summary":"Drugmaker Phathom to break down 2025 results, update in Feb. 26 webcast - Stock Titan","headline":"Drugmaker Phathom to break down 2025 results, update in Feb. 26 webcast","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-10","type":"pipeline","source":"simplywall.st","summary":"Assessing Phathom Pharmaceuticals (PHAT) Valuation After Recent Share Price Volatility - simplywall.st","headline":"Assessing Phathom Pharmaceuticals (PHAT) Valuation After Recent Share Price Volatility","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-08","type":"earnings","source":"simplywall.st","summary":"Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st","headline":"Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27%","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNVk9MbndoOWpfUVhGRzZKX1BuZVpHYTVEUlhQUUpzUno5MldYNUhjWU4yRV96d2s3b0t5bG54LURxVE5oWFJfODhNQnREb3BMckdFcGJWdVRSLU9pbHJFVlVlTmxOWXI1NGFVeEQ5SHdBay1hR2JSSUNuMkF6eE5iXzhYdy0yYjlCSnY5NjBwa0FjVS1hRmVPczJ4cUtWNi1Sc053VjdyYU5ya0JkcWtLUWNVRWJyRHJWNGh5S241Yk4?oc=5","date":"2026-01-07","type":"pipeline","source":"Stock Titan","summary":"Drugmaker developing GI treatments plans new stock and warrant sale - Stock Titan","headline":"Drugmaker developing GI treatments plans new stock and warrant sale","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYmpDZDJncVBibHktM0lHdVREWUhoWTRIV21jX1NnY0xFWGdpd3dkNFFWVVpGNzJWTXJnVzJpd3hoYWRyQmk5NG9mVlRqMHFhSEphWDVKdl9lWk1fVkRXa3FaX2tsX1lqaVJSODFjYjYzeXdUY1ZISkpqSTFDWmlwd1N1bllFYzFnV2Jha085M2k0ZmxvVWRCcVFTdENaWkdZY0JqR0dwRU96Q00?oc=5","date":"2025-11-21","type":"pipeline","source":"Seeking Alpha","summary":"Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth (NASDAQ:PHAT) - Seeking Alpha","headline":"Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth (NASDAQ:PHAT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPSzZBZVdDZmVxVGpEZlQyaE5SYU5INURvaGg1Y1RlbE9CamNVUUF5cVdXX194N010M3Q4aV9YODMxMGhrMUtnREMtTFBpVXBVQjhCaDZCWndsYnZrS051NFlrY19qVDFfcXk1WktrOUV3bm5DRGJYMy0yendlcFU1TVIyU3NGemxC?oc=5","date":"2025-10-30","type":"earnings","source":"Yahoo Finance","summary":"Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance","headline":"Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ...","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQNzhQVExCMHZGd1dkYlNqQ0tHZkRKcFJPTWlFSjAxR3FKbV81bTR1OGR5ZUoxRGN2NXRFbm9lWjdFZnRLcjJrOERtQU1XU3dLbzA4OWFSNkJ5UjdBUTg3LWpLZW9VYmhkX0x4LWpwYVhDYkotRk51UDQ4VjBtRkdyME4yUm5rVUFrYzVxU2tGQTFlc1ZHcTItRkNlb2xrY2wzRGE4Y3EyRnpaWFFUSVU2YjhacVQ2MHZwbl8yT2E2MW9rdklBOEFjNnJBMDBHTXhyMEdHWU5ucnNraENT?oc=5","date":"2025-10-20","type":"earnings","source":"Quiver Quantitative","summary":"Phathom Pharmaceuticals to Hold Conference Call for Q3 2025 Financial Results and Business Update on October 30 - Quiver Quantitative","headline":"Phathom Pharmaceuticals to Hold Conference Call for Q3 2025 Financial Results and Business Update on October 30","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNOE91Tk8xb0RIOWJmWWtfNnZEeU1vaVVWbDRzejVTazMwZmNOTFM2UnVWQ2hvS0JpQ1RzbFVtMHRnQjc4ZlZzRm82b0JuSWhjV2owcGJ6aGJod19kWFpXMkctTExacGJuSS1oSjVpOWRWdXY0S0xJb214QUpOMDhOc0hDdG5JdnJ5cG5oYlNUcXZTTDUtZ3phc0duSlR0TkFZMjhyRHRYYjkzX3dmcVhTaDZ5QQ?oc=5","date":"2025-06-25","type":"pipeline","source":"Seeking Alpha","summary":"Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism - Seeking Alpha","headline":"Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism","sentiment":"neutral"}],"patents":[{"drugName":"Vonoprazan","drugSlug":"vonoprazan","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Takeda Pharmaceutical Company Limited","AstraZeneca","Gilead Sciences"],"therapeuticFocus":["Gastrointestinal (GI) diseases","Gastroesophageal reflux disease (GERD)"],"financials":{"source":"sec_edgar","revenue":175110000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":175110000,"period":"2025-12-31"},{"value":55252000,"period":"2024-12-31"},{"value":55252000,"period":"2024-12-31"},{"value":682000,"period":"2023-12-31"},{"value":682000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":32780000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-221247000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":259149000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":11.92,"previousClose":11.55,"fiftyTwoWeekHigh":18.31,"fiftyTwoWeekLow":2.21,"fiftyTwoWeekRange":"2.21 - 18.31","fiftyDayAverage":11.83,"twoHundredDayAverage":12.29,"beta":0.61,"enterpriseValue":1369323904,"forwardPE":7.7,"priceToBook":-1.94,"priceToSales":5.36,"enterpriseToRevenue":7.82,"enterpriseToEbitda":-8.59,"pegRatio":0,"ebitda":-159352992,"ebitdaMargin":-91,"freeCashflow":-107858128,"operatingCashflow":-166775008,"totalDebt":589171008,"debtToEquity":0,"currentRatio":1.73,"returnOnAssets":-31.4,"returnOnEquity":0,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":10,"targetMeanPrice":23.7,"targetHighPrice":29,"targetLowPrice":13,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.5,"institutionHeldPercent":83.8,"sharesOutstanding":78798712,"floatShares":59233766,"sharesShort":11657728,"shortRatio":12.16,"shortPercentOfFloat":14.8,"epsTrailing":-3.03,"epsForward":1.54,"revenuePerShare":2.4,"bookValue":-6.13,"officers":[{"age":50,"name":"Mr. David A. Socks","title":"Co-Founder"},{"age":66,"name":"Dr. Azmi  Nabulsi M.D., M.P.H.","title":"Co-Founder"},{"age":59,"name":"Mr. Steven L. Basta M.B.A.","title":"CEO, President & Director"},{"age":64,"name":"Mr. Sanjeev  Narula","title":"Chief Financial & Business Officer"},{"age":null,"name":"Mr. Jonathan  Bentley","title":"Senior VP and Head of Sales, Operations & Training"},{"age":null,"name":"Mr. Robert  Breedlove","title":"VP of Finance & Principal Accounting Officer"},{"age":null,"name":"Mr. Eric  Sciorilli","title":"Director of Business Development & Investor Relations"},{"age":null,"name":"Mr. Bill  Aprea J.D.","title":"Senior VP, Chief Compliance Officer & Deputy Chief Legal Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.phathompharma.com","phone":"877 742 8466"}}